A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma

What is the purpose of this trial?

Primary Objective:

  • To compare the progression-free survival (PFS) in patients with previously untreated low grade glioma (LGG) among patients with and without NF-1 utilizing two carboplatin containing regimens; carboplatin/vincristine (SOC) versus single agent carboplatin(research).

Secondary Objectives:

  • To compare the quality of life of children and young adults with LGG treated with carboplatin versus carboplatin and vincristine
  • To estimate tumor response rates to each regimen of chemotherapy.
  • To determine toxicity of each regimen.
  • To assess the associations that BRAF mutations have on clinical outcomes.
  • To assess aberrations found through whole exome and RNA sequencing and correlate with clinical outcome.

Participation Guidelines

Ages: 21 years and younger

Gender: Both


Ann and Robert H. Lurie Children's Hospital of Chicago

Start Date: 07/09/2015

End Date: 04/01/2020

Last Updated: 06/22/2018

Study HIC#: 1504015591

Get Involved

For more information about this study, contact:
Sharon Huie
sharon.huie@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image